References
- Van de Kerkhof PC, Van Erp PE. The role of epidermal proliferation in the pathogenesis of psoriasis. Skin Pharmacol. 1996;9:343–354.
- Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. New treatments for psoriasis: Which biologic is best? J Dermatolog Treat. 2006;17:96–107.
- Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;151(suppl 69):3–17.
- Malaviya R, Sun Y, Tan JK, Wang A, Magliocco M, Yao M, Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients. J Am Acad Dermatol. 2006;55:590–597.
- Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alfa blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum. 2003;48:2155–2162.
- Bedini C, Nasorri F, Girolomoni G, Pità O, Cavani A. Antitumour necrosis factor alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol. 2007;157:249–258.
- Markham T, Mathews C, Rogers S, Mullan R, Bresnihan B, Fitzgerald O, Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy. Br J Dermatol. 2006;155:1191–1196.
- Malaviya R, Sun Y, Tan JK, Magliocco M, Gottlieb AB. Induction of lesional and circulating leukocyte apoptosis by infliximab in a patient with moderate to severe psoriasis. J Drugs Dermatol. 2006;5:890–893.
- Krüger-Krasagakis S, Galanopoulos VK, Giannikaki L, Stefanidou M, Tosca AD. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis. Br J Dermatol. 2006;154:460–466.
- Goedkoop AY, Kraan MC, Teunissen MB, Picavet DI, de Rie MA, Bos JD, Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis. 2004;63:769–773.
- Marble DJ, Gordon KB, Nickoloff BJ. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci. 2007;48:87–101.
- Raj D, Brash DE, Grossman D. Keratinocyte apoptosis in epidermal development and disease. J Invest Dermatol. 2006;126:243–257.
- Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46:1–23; quiz 23–26.
- Qin JZ, Bacon P, Chaturvedi V, Nickoloff BJ. Role of NF-kappaB activity in apoptotic response of keratinocytes mediated by interferon-gamma, tumor necrosis factor-alpha, and tumor-necrosis-factor-related apoptosis-inducing ligand. J Invest Dermatol. 2001;117:898–907.
- Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol. 2005;124:1275–1283.
- Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther. 2008;117:244–279.